BR112023003490A2 - Métodos para prevenção de embolização de cristais de colesterol com ciclodextrinas - Google Patents

Métodos para prevenção de embolização de cristais de colesterol com ciclodextrinas

Info

Publication number
BR112023003490A2
BR112023003490A2 BR112023003490A BR112023003490A BR112023003490A2 BR 112023003490 A2 BR112023003490 A2 BR 112023003490A2 BR 112023003490 A BR112023003490 A BR 112023003490A BR 112023003490 A BR112023003490 A BR 112023003490A BR 112023003490 A2 BR112023003490 A2 BR 112023003490A2
Authority
BR
Brazil
Prior art keywords
methods
embolization
cholesterol crystals
cyclodextrins
prevention
Prior art date
Application number
BR112023003490A
Other languages
English (en)
Portuguese (pt)
Inventor
Kerwin Diana
Camm Jason
Original Assignee
Beren Therapeutics P B C
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beren Therapeutics P B C filed Critical Beren Therapeutics P B C
Publication of BR112023003490A2 publication Critical patent/BR112023003490A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112023003490A 2020-08-27 2021-08-27 Métodos para prevenção de embolização de cristais de colesterol com ciclodextrinas BR112023003490A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063071243P 2020-08-27 2020-08-27
PCT/US2021/048075 WO2022047244A1 (en) 2020-08-27 2021-08-27 Methods for the prevention of cholesterol crystal embolization with cyclodextrins

Publications (1)

Publication Number Publication Date
BR112023003490A2 true BR112023003490A2 (pt) 2023-05-09

Family

ID=80352440

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023003490A BR112023003490A2 (pt) 2020-08-27 2021-08-27 Métodos para prevenção de embolização de cristais de colesterol com ciclodextrinas

Country Status (11)

Country Link
US (1) US20230302042A1 (https=)
EP (1) EP4203973A4 (https=)
JP (1) JP2023543132A (https=)
KR (1) KR20230096976A (https=)
CN (1) CN116635007A (https=)
AU (1) AU2021331485A1 (https=)
BR (1) BR112023003490A2 (https=)
CA (1) CA3190764A1 (https=)
IL (1) IL300881A (https=)
MX (1) MX2023002420A (https=)
WO (1) WO2022047244A1 (https=)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4877778A (en) * 1987-07-01 1989-10-31 The Children's Medical Center Corporation Method of enhancing lipophile transport using cyclodextrin derivatives
MX371073B (es) * 2012-04-13 2020-01-15 L&F Res Llc Método para utilizar ciclodextrina.

Also Published As

Publication number Publication date
KR20230096976A (ko) 2023-06-30
CA3190764A1 (en) 2022-03-03
EP4203973A4 (en) 2024-08-21
US20230302042A1 (en) 2023-09-28
JP2023543132A (ja) 2023-10-13
MX2023002420A (es) 2023-07-11
IL300881A (en) 2023-04-01
CN116635007A (zh) 2023-08-22
EP4203973A1 (en) 2023-07-05
AU2021331485A1 (en) 2023-03-23
WO2022047244A1 (en) 2022-03-03

Similar Documents

Publication Publication Date Title
Ducrocq et al. Epidemiology and early predictive factors of mortality and outcome in children with traumatic severe brain injury: experience of a French pediatric trauma center
Collinge et al. The effects of clopidogrel (Plavix) and other oral anticoagulants on early hip fracture surgery
BR112022011951A2 (pt) Tratamento de esclerose lateral amiotrófica e distúrbios relacionados
BR112023003455A2 (pt) Métodos para o tratamento de embolização por cristais de colesterol com ciclodextrinas
Bigot et al. Unexpected platelets elevation in a patient with idiopathic thrombocytopenia treated with oseltamivir for influenza infection
Kosucu et al. Effects of perioperative magnesium sulfate with controlled hypotension on intraoperative bleeding and postoperative ecchymosis and edema in open rhinoplasty
Lee et al. Cardiopulmonary arrest following administration of Cyclomydril eyedrops for outpatient retinopathy of prematurity screening
Shah et al. Direct oral anticoagulants (DOACs) and neck of femur fractures: standardising the perioperative management and time to surgery
Ktenopoulos et al. Direct oral anticoagulants in patients on chronic dialysis and concomitant atrial fibrillation: a common clinical impasse
Bhalla et al. Silent sinus syndrome: interesting clinical and radiologic findings
BR112023003490A2 (pt) Métodos para prevenção de embolização de cristais de colesterol com ciclodextrinas
Spidey et al. Bullous pemphigoid: corticosteroid treatment and adverse effects in long-term care patients
AU2023271764A1 (en) Combination of taurursodiol and sodium phenylbutyrate for treating amyotrophic lateral sclerosis
Chang et al. Lamotrigine-associated anticonvulsant hypersensitivity syndrome in bipolar disorder
Finsterer Lobar bleeding with ventricular rupture shortly after first dosage of an mRNA-based SARS-CoV-2 vaccine
Tudor et al. Nursing implications for the lifelong management of tuberous sclerosis complex
Colwell et al. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery
Psevdos Jr et al. Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis
Rowe et al. Seasonal human influenza: treatment options
Ivanov Meconium aspiration syndrome treatment–new approaches using old drugs
Vilaça et al. Anesthetic considerations for a patient with hereditary angioedema-A clinical case
Farkas et al. Human plasma-derived, nanofiltered, C1-inhibitor concentrate (Cinryze®), a novel therapeutic alternative for the management of hereditary angioedema resulting from C1-inhibitor deficiency
Khurshid et al. Self-medication of corticosteroids: a life threatening case report from Pakistan
Singh et al. A case of coumarin embryopathy after in utero exposure to acenocoumarol
Shhada et al. Un-diagnosed coarctation of the aorta in a 27-year-old adult with a rare presentation: a rare case report

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]